The main strengths of this study include the large-scale multicenter dataset with available amyloid PET, tau PET and longitudinal clinical and cognitive data, which allowed us to accurately estimate the relative risk of the different AT groups in terms of clinical progression and cognitive decline. This evidence concerns the gene MAPT and ataxia telangiectasia.